Business
Benlysta Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
Key market opportunities for Benlysta include strong growth momentum driven by sustained sales and strategic expansion into lupus nephritis. The shift to subcutaneous administration enhances patient convenience and market penetration. Increasing adoption of biologics in lupus treatment further strengthens Benlysta's position as a key player in GlaxoSmithKline's immunology portfolio.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Benlysta Sales Forecast and Market Size Analysis - 2034" has been add
About this update from Gsk Plc
Key market opportunities for Benlysta include strong growth momentum driven by sustained sales and strategic expansion into lupus nephritis. The shift to subcutaneous administration enhances patient convenience and market penetration. Increasing adoption of biologics in lupus treatment further strengthens Benlysta's position as a key player in GlaxoSmithKline's immunology portfolio. Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Benlysta Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report offers insights into Benlysta's uses, sales forecasts, mechanism of action, and potential indications across major global markets, including the U.S., Europe, and Japan. It provides a comprehensive examination of current and future market scenarios, placing emphasis on research, development, and the competitive landscape. Benlysta (Belimumab) is a recombinant monoclonal antibody for systemic lupus erythematosus (SLE) and lupus nephritis, targeting B-lymphocyte stimulator. Clinical trials demonstrate its efficacy in reducing disease activity and flares, generally well tolerated with common side effects including nausea and fever. GSK has enhanced production capacity for Benlysta, investing $139 million in its Maryland site as of 2017. These developments underpin the subcutaneous form's support. Key Factors Driving Benlysta Growth Strong and Sustained Sales Growth Momentum First-in-Class BLyS (BAFF) Inhibitor Expansion into Lupus Nephritis Shift Toward Subcutaneous Administration Increasing Adoption of Biologics Benlysta Recent Developments Scope of the Benlysta Market Report Key Questions For more information about this report visit https://www.researchandmarkets.com/r/tzwzxx About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900